Neurocrine Biosciences Altman Z-Score
NBIX / Health Care|Modified Z-Score (book value) based on FY2025 data
Neurocrine Biosciences's Altman Z-Score of 2.38 places the company in the "grey zone" (1.23–2.9). This range has historically shown mixed outcomes in the Altman model (FY2025). Z-Score is calculated from 5 financial ratios derived from Neurocrine Biosciences's SEC 10-K filing, evaluated in the context of the Health Care sector.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Grey Zone (1.23 - 2.9)
Grey zone - moderate risk, requires monitoring
The Altman Z-Score predicts bankruptcy risk using 5 financial ratios. Learn more
Profit margin ranks in the below average of Health Care companies
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2025 10-K filings.
5-Factor Decomposition
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.384 | 0.717 | 0.275 |
| Retained Earnings / Total Assets | 0.097 | 0.847 | 0.082 |
| EBIT / Total Assets | 0.134 | 3.107 | 0.415 |
| Book Equity / Total Liabilities | 2.360 | 0.420 | 0.991 |
| Revenue / Total Assets | 0.618 | 0.998 | 0.616 |
| Total Z-Score | 2.38 | ||
As of FY2025 · SEC 10-K · Updated Feb 28, 2026
Z-Score Zones
Safe Zone - Company is in strong financial health with low bankruptcy risk.
Grey Zone - Uncertain financial position. Requires closer monitoring.
Distress Zone - Elevated probability of financial difficulties.